CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $56.42M, above the global median of $18.73M
- PositionOperating margin is 76%, higher than 95% of its Biotechnology peers (median -24.1%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
1.05BUSDvs all stocks (USD)
Trailing P/E
13.30xvs Biotechnology peers
Revenue (TTM)
397.50MUSDvs all stocks (USD)
Profit Margin
19.87%vs Biotechnology peers
Beta
1.27xvs all stocks
52-Week Change
32.24%vs all stocks
Market Capitalization
1.05BUSDvs all stocks (USD)
Enterprise Value
1.02BUSDvs all stocks (USD)
Trailing P/E
13.30xvs Biotechnology peers
Forward P/E
-7.15xvs Biotechnology peers
PEG Ratio
-0.0285xvs Biotechnology peers
Price to Sales (TTM)
2.64xvs Biotechnology peers
Price to Book (MRQ)
4.77xvs Biotechnology peers
Enterprise to Revenue
2.56xvs Biotechnology peers
Enterprise to EBITDA
5.19xvs Biotechnology peers
Gross Margin
97.77%vs Biotechnology peers
Profit Margin
19.87%vs Biotechnology peers
Operating Margin
76.04%vs Biotechnology peers
Return on Assets (TTM)
38.65%vs Biotechnology peers
Return on Equity (TTM)
72.17%vs Biotechnology peers
Revenue (TTM)
397.50MUSDvs all stocks (USD)
Revenue per Share (TTM)
4.75USDUpdated Sep 28, 2026Quarterly Revenue Growth
8608.60%vs Biotechnology peers
Gross Profit (TTM)
389.35MUSDvs all stocks (USD)
EBITDA (TTM)
196.13MUSDvs all stocks (USD)
Net Income (TTM)
78.98MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
8608.59%vs Biotechnology peers
Operating Cash Flow (TTM)
13.69MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
56.42MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
81.39MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
4.84MUSDFY2025 · Dec 31, 2025Gross Profit
76.55MUSDFY2025 · Dec 31, 2025Operating Income
-105.97MUSDvs all stocks (USD)
Pre-tax Income
-114.20MUSDFY2025 · Dec 31, 2025Net Income
-114.20MUSDFY2025 · Dec 31, 2025EBIT
-102.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-91.54MUSDFY2025 · Dec 31, 2025Research & Development
129.62MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
52.90MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.82MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
12.20MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.42USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.42USDFY2025 · Dec 31, 2025Basic Shares Outstanding
80.43MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
80.43MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-114.20MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-49.70MUSDFY2025 · Dec 31, 2025Free Cash Flow
-53.39MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
68.19MUSDFY2025 · Dec 31, 2025Interest Paid
11.04MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-114.20MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
12.61MUSDFY2025 · Dec 31, 2025Stock-based Compensation
22.11MUSDFY2025 · Dec 31, 2025Other Non-cash Items
6.89MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-7.27MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-12.31MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
42.48MUSDFY2025 · Dec 31, 2025Capital Expenditures
-3.70MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-410.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.70MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-29.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-3.03MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
12.02MUSDFY2025 · Dec 31, 2025Shares Outstanding
94.19MSharesUpdated Sep 28, 2026Float Shares
53.75MSharesUpdated Sep 28, 2026Shares Short
4.01MSharesUpdated Sep 28, 2026Short Ratio
5.38daysvs all stocks
Short % of Shares Outstanding
5.83%vs all stocks
% Held by Insiders
16.39%vs all stocks
% Held by Institutions
70.48%vs all stocks
Total Cash (MRQ)
143.17MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.49USDUpdated Sep 28, 2026Total Debt (MRQ)
112.32MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.5205xvs Biotechnology peers
Current Ratio (MRQ)
3.76xvs Biotechnology peers
Book Value per Share (MRQ)
2.29USDUpdated Sep 28, 2026Total Assets
244.43MUSDvs all stocks (USD)
Total Current Assets
91.76MUSDFY2025 · Dec 31, 2025Total Liabilities
250.22MUSDFY2025 · Dec 31, 2025Total Non-current Assets
152.67MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
127.67MUSDFY2025 · Dec 31, 2025Total Current Liabilities
122.56MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
65.93MUSDFY2025 · Dec 31, 2025Accounts Receivable
3.00MUSDFY2025 · Dec 31, 2025Inventory
0.00USDFY2025 · Dec 31, 2025Accounts Payable
10.07MUSDFY2025 · Dec 31, 2025Short-term Debt
27.54MUSDFY2025 · Dec 31, 2025Deferred Revenue
1.78MUSDFY2025 · Dec 31, 2025Other Current Liabilities
50.28MUSDFY2025 · Dec 31, 2025Long-term Debt
61.15MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-816.22MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-5.79MUSDvs all stocks (USD)
52-Week Low
6.62USDUpdated Sep 28, 202652-Week High
15.35USDUpdated Sep 28, 202652-Week Change
32.24%vs all stocks
Beta
1.27xvs all stocks
50-Day MA
13.01USDUpdated Sep 28, 2026200-Day MA
10.04USDUpdated Sep 28, 2026Avg 10-Day Volume
1.16MSharesUpdated Sep 28, 2026Avg 30-Day Volume
885.93KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
0.8200USDUpdated Sep 28, 2026Other Income / Expense
2.15MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 76%, higher than 95% of its Biotechnology peers (median -24.1%)Significant
Operating margin: 0.76Industry median: -0.24Industry P95: 0.38Peers compared: 193
Return on equity is 72.2%, higher than 95% of its Biotechnology peers (median -23.6%)Significant
Return on equity: 0.72Industry median: -0.24Industry P95: 0.23Peers compared: 193
Return on assets is 38.7%, higher than 95% of its Biotechnology peers (median -21.2%)Significant
Return on assets: 0.39Industry median: -0.21Industry P95: 0.19Peers compared: 193
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 78,982,000Operating Cash Flow (USD, TTM): 13,689,000
Financial Health
Consistent revenue growth patternNotable
Growth Consistency Score: 0.54
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $56.42M, above the global median of $18.73MNotable
Levered free cash flow (USD): 56,421,000Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Star Lake Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jiangsu Kanion Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zylox-Tonbridge Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xiangyu Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Hongyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Aidea Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inkon Life Tech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alto Neuroscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Guilin Sanjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Savannah Energy PLC
1 interpretationWithin or Near the Altman Distress Zone
Highbroad Advanced Material Co. Ltd.
1 interpretationWithin or Near the Altman Distress Zone
Risen Energy Co., Ltd.
1 interpretationWithin or Near the Altman Distress Zone